F M Investments LLC decreased its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 67.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 52,918 shares of the company's stock after selling 108,608 shares during the period. F M Investments LLC owned about 0.11% of Prestige Consumer Healthcare worth $4,132,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently bought and sold shares of PBH. Kestra Investment Management LLC purchased a new stake in shares of Prestige Consumer Healthcare during the fourth quarter valued at $27,000. CIBC Private Wealth Group LLC raised its stake in Prestige Consumer Healthcare by 48.9% during the fourth quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock worth $34,000 after acquiring an additional 152 shares in the last quarter. Headlands Technologies LLC bought a new position in shares of Prestige Consumer Healthcare in the fourth quarter valued at about $40,000. GAMMA Investing LLC lifted its position in Prestige Consumer Healthcare by 18.9% during the 4th quarter. GAMMA Investing LLC now owns 1,383 shares of the company's stock valued at $108,000 after purchasing an additional 220 shares during the period. Finally, Huntington National Bank grew its stake in Prestige Consumer Healthcare by 133.2% in the fourth quarter. Huntington National Bank now owns 1,481 shares of the company's stock valued at $116,000 after acquiring an additional 846 shares during the period. 99.95% of the stock is owned by institutional investors.
Insider Activity at Prestige Consumer Healthcare
In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $90.00, for a total value of $151,020.00. Following the completion of the transaction, the senior vice president now owns 17,157 shares in the company, valued at approximately $1,544,130. This represents a 8.91 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.60% of the stock is currently owned by insiders.
Prestige Consumer Healthcare Price Performance
NYSE:PBH traded down $0.05 during mid-day trading on Wednesday, reaching $80.89. 85,679 shares of the stock were exchanged, compared to its average volume of 284,642. Prestige Consumer Healthcare Inc. has a 1-year low of $62.35 and a 1-year high of $90.04. The business has a fifty day moving average price of $84.56 and a 200 day moving average price of $79.97. The firm has a market capitalization of $4.01 billion, a PE ratio of 18.94, a PEG ratio of 2.69 and a beta of 0.47. The company has a current ratio of 3.68, a quick ratio of 2.20 and a debt-to-equity ratio of 0.56.
Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $1.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. Research analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
PBH has been the topic of a number of recent research reports. Raymond James raised shares of Prestige Consumer Healthcare to a "moderate buy" rating in a research report on Thursday, December 19th. Oppenheimer raised their price target on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an "outperform" rating in a research note on Thursday, February 13th. Canaccord Genuity Group increased their price target on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a "buy" rating in a report on Friday, February 7th. StockNews.com cut shares of Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a report on Tuesday, April 8th. Finally, Royal Bank of Canada increased their price objective on Prestige Consumer Healthcare from $96.00 to $97.00 and gave the company a "sector perform" rating in a research report on Friday, March 21st. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $93.33.
Get Our Latest Stock Analysis on Prestige Consumer Healthcare
About Prestige Consumer Healthcare
(
Free Report)
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Further Reading
Before you consider Prestige Consumer Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prestige Consumer Healthcare wasn't on the list.
While Prestige Consumer Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
